The Pharmaceutical Mental Health Initiative (PMHI) group is made up of ABPI member companies with an interest in mental health. Its aim is to create a positive environment for the use of modern medicines to treat patients across the spectrum of serious mental illness. The PMHI is a group of three pharmaceutical companies with an interest in the field of mental health.
Improving outcomes in mental health by ensuring optimal access to innovative medicines
To represent individual member companies and the wider industry on all issues related to access to medicines for people with mental illnesses, including schizophrenia, bipolar disorder, depression and dementia.
The Industry and Mental Health Services Collaborative (IMHSeC) is a partnership between the Pharmaceutical Mental Health Initiative (PMHI), a working group of the ABPI, the Department of Health, Mental Health Directorate and the NHS Confederation.
The Cluster Pathway Guide is a collaborative project under the IMHSeC partnership. The project stakeholders include the London School of Economics (LSE) and the Care Pathways and Packages Project (CPPP). It is the first national web-based support resource to enable organisations to integrate Payment by Results (PbR) into the mental health system. The site provides resources designed to give a high level overview of good practice and evidence informed care for each of the 21 clusters.
The National Mental Health Activity Codes Project is an ongoing collaborative project under the IMHSeC partnership. The project stakeholders include the NHS Information Centre, LSE and the CPPP. The aim of the project is to produce a report that recommends a new set of mental health activity codes to help standardise the way in which organisations record their data. This project will enable the NHS to benchmark and compare performance uniformly across similar healthcare organisations.
This PMHI project is in collaboration with York Health Economics Consortium (YHEC). The project's overall aim is to provide evidence to consider whether or not funding streams for innovative mental health medications are consistent with those for innovative medications for other health conditions, in NHS England. The report will provide evidence to support the development and uptake of innovation in mental health.
For more information on any of these projects, please email Miranda Stead, Director Mednet, at [email protected].